RCT: Among premature infants with a gestational age of less than 30 weeks and intubated for at least 7 days at 14 to 28 days, hydrocortisone did not improve survival without bronchopulmonary dysplasia.

Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia – New England Journal of Medicine (link to abstract – $ for full-text)

See also: Visual Abstract

Related:

Randomized Trial: Effect of Hydrocortisone on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation

Systematic Review: Late (after 6 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Systematic Review: Early (started within six days) systemic postnatal corticosteroids for preventing bronchopulmonary dysplasia in preterm infants.

State of the Art Review: Diagnosis and management of bronchopulmonary dysplasia.

M-A: Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates

ERS Guideline on Long-term Management of Children with Bronchopulmonary Dysplasia

Commentary on Twitter

In this trial involving preterm infants, there was little difference in survival without bronchopulmonary dysplasia or in the occurrence of neurodevelopmental impairment with hydrocortisone as compared with placebo. https://t.co/wzGQ1gohjA pic.twitter.com/yfrIaG3JLv

— NEJM (@NEJM) March 23, 2022